Working from home? Keep up to date with the latest sequencing technology for mutation detection by joining a webinar on Thursday March 26th on Duplex Sequencing. To register, click here.
Title: Duplex Sequencing™ Technology: Transforming Safety Testing
Date: Thursday, March 26, 2020
Time: 11:00 AM Eastern Daylight Time
Duration: 1 hour
Bob Young, MS
Program Consultant and Study Director, In Vivo Mutation
Merck KGaA, Darmstadt, Germany
Jesse Salk, MD, PhD
CEL, CSO and Founder
In this webinar, you will learn about:
- Duplex Sequencing™ technology unmatched sensitivity and accuracy in NGS applications
- Duplex technology applications in identification of carcinogenic chemicals
- Global efforts to evaluate and adopt Duplex Sequencing™ technology for regulatory submission
- Applications in drug and chemical safety assessment
Duplex Sequencing™ technology is a new error-corrected NGS method that improves sequencing accuracy 100,000-fold. This increase in accuracy opens the door to significant reductions in time spent in drug development, allowing measurement of a compound’s carcinogenic risk months or even years earlier than current methods. DS technology now permits early measurement of ultra-rare new mutants. We will discuss the technology, clinical applications and then explore nonclinical safety assessment applications. Mouse and rat mutation data will be presented from various mutagens, tissues and genes. Mutant frequency data and mutational “fingerprint” data will be discussed in context of human tumors. Plans for collaborative qualification through the HESI Genetic Toxicology Technical Committee will be discussed.